The US Army Medical Research Acquisition Activity (USAMRAA) intends to negotiate, on a sole source basis, under authority of 41 U.S.C. 253(c), with Boston University to further work performed in crystallization using our small molecule inhibitors. Services are required for the USA Med Research Institute of Infectious Diseases (USAMRIID) at for Detrick.

Sole source determination is based on the Governments need for a contractor with
(a) extensive expertise, crystallization and high resolution diffraction of the BoNT light chain protein and its structural interaction by a N-Ac-CRATKML peptide inhibitor.
(b) Success of diffracting at 1.2 angstroms (see article in Biochemistry (2008) 47,5736-5745.

Boston university is uniquely qualified to meet the Governments need due to its published work on the successful crystallization and high resoluction diffraction of the BoNT light chain protein and its structural interaction by N-Ac-CRATKML peptide inhibitor. The resolution ( the highest now available) is an important step towards developing effective drug therapies against botulinum neurotoxin.

The period of performance will be one year, with work to be performed at the USAMRIID, Fort Detrick, MD facility.

No solicitation package will be issued. This notice of intent is not a request for competitive quotations. However, responses received by September 11, 2008, will be considered by the Government. A determination by the Government not to compete the proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.

Bid Protests Not Available